Schultz Shoots Back At Maisel In NEJM, Explains Handling Of Fidelis Recall
This article was originally published in The Gray Sheet
Executive Summary
In a letter in the July 3 New England Journal of Medicine, CDRH Director Dan Schultz defends FDA's approval of some devices based only on bench testing data
You may also be interested in...
Heart Rhythm Experts Release New Pacer/ICD Lead Management Guidelines
New recommendations from leading heart experts call on physicians, device manufacturers and FDA to do a better job monitoring and managing the safety of pacemaker and implantable defibrillator leads
Heart Rhythm Experts Release New Pacer/ICD Lead Management Guidelines
New recommendations from leading heart experts call on physicians, device manufacturers and FDA to do a better job monitoring and managing the safety of pacemaker and implantable defibrillator leads
Experts Call For Better Pre-clinical ICD Lead Testing
The current standard of pre-clinical testing for ICD leads is inadequate, but efforts to improve lead design and safety are underway, according to the new president of the Heart Rhythm Society